Recombinant Mouse Fractalkine (Fragmented)
| Code | Size | Price |
|---|
| LEI-F1040-25ug | 25 ug | £614.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Regulatory Status: RUO
Shipping:
Ambient
Storage:
This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
Further Information
Format:
This recombinant protein was lyophilized from a 0.2 um filtered solution in 35% acetonitrile (CH3CN) and 0.1% trifluoroacetic acid (TFA).
Formulation:
This recombinant protein was lyophilized from a 0.2 um filtered solution in 35% acetonitrile (CH3CN) and 0.1% trifluoroacetic acid (TFA).
Long Description:
Fractalkine (FKN) is a transmembrane mucin-chemokine hybrid molecule expressed on activated endothelium1 that mediates attachment and firm adhesion of T cells, monocytes and NK cells.2 FKN plays an important proinflammatory role in rheumatoid arthritis (RA) pathogenesis as characterized by induction of synovial angiogenesis, chemotaxis, activation of monocytes and T cells as well as the stimulation of proliferation and synthesis of matrix degrading enzymes (matrix metalloproteinases, MMP) in synovial fibroblasts. Fractalkine thus may represent a novel target molecule for therapeutic intervention in RA.3 FKN is also an essential biomarker for predicting the prognosis of patients with colorectal cancer (CRC).4
NCBI Gene:
20312
Purity:
>95% by SDS-PAGE and analyzed by silver stain.
Target:
CX3CL1
References
1. Patel, DD. et al. (1998) J Exp Med. 188: 1413
2. Hwang, ST. et al. (1999) Eur J Immunol. 29: 2551
3. Muller, GA. et al. (2008) Z Rheumatol. 67: 424
4. Mori, M. et al. (2005) Int J Oncol. 26: 41
Related Products
| Product Name | Product Code | Supplier | Anti-Human CX3CL1- Biotin | LEI-C1492 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant Human CX3CL1/Fractalkine (FKN) | LEI-F1030 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Human CX3CL1/Fractalkine Protein | LEI-F116 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||